THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...

Atara is working closely with its partners and the FDA to lift clinical hold and support EBVALLO ™ BLA resubmission in the U.S. Atara remains focused on delivering on the future financial value of ...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...

Canaccord raised the firm’s price target on Atara Biotherapeutics (ATRA) to $25 from $17 and keeps a Buy rating on the shares. The firm said they ...

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients ...

Atara Biotherapeutics experiences a plunge in share prices after the Food and Drug Administration holds up approval of a drug candidate. Atara Biotherapeutics' headquarters in Thousand Oaks. The share ...

Atara has transferred all manufacturing responsibility to Pierre Fabre Laboratories, including all costs associated with the manufacturing and supply of tabelecleucel for development and ...

Atara Biotherapeutics' headquarters in Thousand Oaks. The announcement by Atara Biotherapeutics Inc. that it was raising $36 million through a registered direct offering sat well with investors.

A fatality in an early-stage clinical trial is weighing on the cell therapy company's stock today. Ahead of the opening bell, Atara announced that Memorial Sloan Kettering Cancer Center (MSK), where ...

The U.S. Food and Drug Administration (FDA) has accepted the filing of Atara’s Biologics License Application (BLA) for tabelecleucel (tab-cel®) indicated as monotherapy for treatment of adult and ...